SEATTLE--(BUSINESS WIRE)--Cardiothoracic surgeons and cardiologists attending the 95th annual meeting of the American Association of Thoracic Surgeons will hear a panel of clinical experts discussing the FDA’s recent decision allowing patients with aortic heart valves from On-X® Life Technologies Inc. (ONXLTI) to reduce their warfarin anticoagulation regimen and be managed, starting three months after their surgery, at an INR (International Normalized Ratio) level of 1.5 to 2.0, which is closer to an unmedicated INR.
Help employers find you! Check out all the jobs and post your resume.
